首页> 美国卫生研究院文献>TH Open: Companion Journal to Thrombosis and Haemostasis >Use of Targeted High-Throughput Sequencing for Genetic Classification of Patients with Bleeding Diathesis and Suspected Platelet Disorder
【2h】

Use of Targeted High-Throughput Sequencing for Genetic Classification of Patients with Bleeding Diathesis and Suspected Platelet Disorder

机译:有针对性的高通量测序在出血素质和疑似血小板异常患者的遗传分类中的应用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Inherited platelet disorders (IPD) form a rare and heterogeneous disease entity that is present in about 8% of patients with non-acquired bleeding diathesis. Identification of the defective cellular pathway is an important criterion for stratifying the patient's individual risk profile and for choosing personalized therapeutic options. While costs of high-throughput sequencing technologies have rapidly declined over the last decade, molecular genetic diagnosis of bleeding and platelet disorders is getting more and more suitable within the diagnostic algorithms. In this study, we developed, verified, and evaluated a targeted, panel-based next-generation sequencing approach comprising 59 genes associated with IPD for a cohort of 38 patients with a history of recurrent bleeding episodes and functionally suspected, but so far genetically undefined IPD. DNA samples from five patients with genetically defined IPD with disease-causing variants in WAS , RBM8A , FERMT3 , P2YR12 , and MYH9 served as controls during the validation process. In 40% of 35 patients analyzed, we were able to finally detect 15 variants, eight of which were novel, in 11 genes, ACTN1 , AP3B1 , GFI1B,HPS1,HPS4,HPS6,MPL,MYH9,TBXA2R,TPM4, andTUBB1, and classified them according to current guidelines. Apart from seven variants of uncertain significance in 11% of patients, nine variants were classified as likely pathogenic or pathogenic providing a molecular diagnosis for 26% of patients. This report also emphasizes on potentials and pitfalls of this tool and prospectively proposes its rational implementation within the diagnostic algorithms of IPD.
机译:遗传性血小板疾病(IPD)形成一种罕见的异质性疾病实体,约有8%的未获得性出血素质的患者中存在这种疾病。缺陷细胞通路的鉴定是分层患者个人风险概况和选择个性化治疗选择的重要标准。在过去的十年中,尽管高通量测序技术的成本迅速下降,但出血和血小板疾病的分子遗传学诊断在诊断算法中变得越来越适用。在这项研究中,我们开发,验证和评估了针对性的,基于专家组的下一代测序方法,该方法包含了与IPD相关的59个基因,用于38例具有复发性出血发作史且功能可疑,但迄今为止在遗传学上尚不确定的患者IPD。在验证过程中,来自5名具有遗传定义IPD且在WAS,RBM8A,FERMT3,P2YR12和MYH9中引起疾病​​的变异的患者的DNA样品用作对照。在分析的35位患者中,有40%的患者最终能够检测出11个基因ACTN1,AP3B1,GFI1B中的15个变体,其中8个是新变体,HPS1,HPS4,HPS6,MPL,MYH9,TBXA2R,TPM4和管1,并根据当前指南对其进行分类。除了11%的患者中7种不确定性显着的变体之外,还有9种变体被归类为可能的致病性或致病性,可为26%的患者提供分子诊断。该报告还强调了该工具的潜力和陷阱,并在IPD的诊断算法中前瞻性地提出了该工具的合理实施。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号